Geftinat (Iressa) Gefitinib - A Medicine for Advanced Non-Small Cell Lung Cancer

Geftinat Gefitinib Iressa
Lung cancer is the most common cancer in the world. In the United States, lung cancer is the second most common cancer in both men and women (without skin cancer) and yet the leading cause of cancer death in both men and women. In the United States alone, around 13% of all new cancer diagnoses are expected to be included in 2018. Lung cancer affects the cells or tissues of the lungs and can spread to other parts of the body.

Treat: It’s time to act.

While many people who have lung cancer - may be more than willing to start fighting cancer, every treatment option has special considerations that could affect their daily lives. Although the treatment options and side effects vary, discuss the treatment options with your doctor, including the risks and potential benefits.

Taking Geftinat Gefitinib (Iressa)

Geftinat is a targeted therapy for the treatment of non-small cell lung carcinoma (NSCLC) with a specific epidermal growth factor receptor mutation (EGFR). It is designed to block the activating sites (tyrosine kinases) of various proteins in the cancer cell. These proteins can stimulate cancer growth if the tumor has an EGFR mutation. By blocking the action of the proteins, Geftinat can shrink the cancer or slow the progression of the cancer.

Geftinat is a pill that is taken orally once a day. It can be taken with or without food. The dosage of Geftinat is determined by several factors, including the patient's overall health and ongoing response to treatment...Continue Reading More

Photo Gallery

0 Comments Write your comment

    1. Loading...